RxDoctor Payments Data

Roxanne Pero

Dallas, TXNPI 1508069790

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 35.2% of the total. Reporting peaked in 2021 at $429 and has fallen 96.7% since, to $14 in 2025.

$1,120in general payments, 2019–2025

Across 74 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • Avanos Medical$92
  • Therapeuticsmd, Inc.$69
  • Smith+Nephew$68
  • Pfizer$55
  • Vertical Pharmaceuticals, LLC$51
  • plus $392 from 17 others
$1,324,978in research payments, 2019–2025

Across 137 payments — averaging $9671.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$840K
  • GSK$485K

What the payments were for

  • Food & beverage$1,09498%
  • Education$262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →